The p53 protein is engaged in the repair of DNA mutations and elimination of heavily damaged cells, providing anticancer protection. Dysregulation of p53 activity is a crucial step in carcinogenesis. This dysregulation is often caused by the overexpression of negative regulators of p53, among which MDM2 is the most prominent one. Antagonizing MDM2 with small molecules restores the activity of p53 in p53 wild-type (p53 wt ) cells and thus provides positive outcomes in the treatment of p53 wt cancers. Previously, we have reported the discovery of a panel of fluoro-substituted indole-based antagonists of MDM2. Here, we demonstrate the biological activity and stereoselectivity of the most active compound from this series. Both enantiomers of the esterified form of the compound, as well as its corresponding carboxylic acids, were found active in fluorescence polarization (FP) assay, nuclear magnetic resonance (NMR) and microscale thermophoresis (MST) assay, with K i and K D values around 1 lM. From these four compounds, the esterified enantiomer (R)-5a was active in cells, which was evidenced by the increase of p53 levels, the induced expression of p53-target genes (CDKN1A and MDM2), the selective induction of cell cycle arrest, and selective growth inhibition of p53 wt U-2 OS and SJSA-1 compared to p53 del SAOS-2 cells. The analysis of the crystal structure of human MDM2 in complex with the compound (R)-6a (carboxylic acid of the active (R)-5a compound) revealed the classical three-finger binding mode. Altogether, our data demonstrate the activity of the compound and provide the structural basis for further structure optimization.
Introduction
The protein p53 is a well-known tumor suppressor, activated in a response to several different stimuli, including DNA damage. Due to its tumor-suppressive activity, p53 is dysregulated in almost every single cancer [1] . It is estimated that 50% of cancers inactivate p53 by gaining loss-of-function mutations or deletions Abbreviations BSA, bovine serum albumin; DMSO, dimethyl sulfoxide; DTT, dithiothreitol; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; FP, fluorescence polarization; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HSQC, heteronuclear single quantum coherence; IPTG, isopropyl b-D-1-thiogalactopyranoside; MCR, multicomponent reaction; MDM2, murine double minute-2; MDMX, murine double minute-X; MME, monomethyl ether; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide; NMR, nuclear magnetic resonance spectroscopy; PBS, phosphate-buffered saline; PEG, polyethylene glycol; PVDF, polyvinylidene fluoride; RMSD, root-mean-square deviation; TBS, tris-buffered saline.
in the TP53 gene [2] . The remaining 50% of cancers utilize natural mechanisms of negative regulation of p53, enhanced to the extent that disallows its activation. In this regard, the increase of the inhibitory potential of MDM2 protein is the most common way to keep p53 inactive. MDM2 has the ability to inhibit p53 in the two different ways: by masking the transactivation domain of p53, and by directly ubiquitinating p53, directing the protein to proteasomal degradation [3] . The gene encoding MDM2 protein is very frequently amplified in human cancers, leading to MDM2 overexpression [3] . Overexpressed MDM2 binds to p53, leading to the permanent inactivation of this protein. Accordingly, forced disruption of p53/ MDM2 complexes became a favored strategy of the restoration of p53 functioning in p53 wt cancers [4] . Over the last years, numerous small molecule scaffolds have been proposed that are able to disrupt the MDM2/p53 complexes. Among these compounds, several presented truly promising preclinical results and are currently undergoing clinical trials [5] . This includes small molecule derivatives of nutlin-3, RG7112, and RG7388 from Roche [6, 7] , the successor of AM-8553 compound, AMG 232 from Amgen [8] , CGM097 and HDM201 from Novartis [9] , and spirooxindole compounds, SAR405838 (MI-77301) from Sanofi [10] , DS-3032b from Daiichi Sankyo [11] , and APG-115 from Ascentage Pharma Group [12] . Moreover, several stapled peptides have been described with high affinity toward MDM2 and MDMX, with representative molecule, ALRN-6924 (Aileron Therapeutics), currently undergoing phase I and II clinical trials in patients suffering from solid tumors, lymphoma, and myeloid leukemias [5] .
In recent years, we have successfully designed and synthesized MDM2 antagonists based on the wellrecognized three-point binding model using a pharmacophore-based screening approach and multicomponent reaction chemistry [13] [14] [15] [16] [17] [18] [19] [20] [21] . Among these reports, we have reported the design, synthesis, and activity of a library of MDM2 antagonists, substituted with fluorine at various positions and synthesized by a classical Ugi four-component reaction (U-4CR) [22] . We showed that the introduction of fluorine substituents to the benzyl group can considerably improve the in vitro MDM2 binding activity of the antagonists due to the electrostatic interaction between small molecules and the His96 residue of the protein. We have then identified the most active compound, which was able to disrupt the p53/MDM2 interaction with K i values of 0.13 lM and 0.4 lM for the corresponding acid and ester form, respectively [22] . In the current report, we demonstrate the biological activity of our most potent trifluoro-substituted compound in comparison to known MDM2 antagonists nutlin-3a and Idasanutlin (RG7388). In addition, we report the structural basis of the interaction of our compound (de-esterified) with human MDM2 protein for further structure-based optimization of its properties.
Results
The synthesis of the compounds Based on our previous work [22] , we resynthesized and scaled-up the most promising trifluoro-substituted compound ( Fig. 1) for further evaluation of its activity employing biochemical, biophysical, and cellular assays. The synthesis involves a convergent Ugi 4-component reaction and the MDM2 antagonists can be assembled in just two steps from commercially available starting materials [22] . The equimolar mixing of the 3,4,5-trifluorobenzylamine (1), indole-3-carboxaldehyde (2), tert-butyl isocyanide (3), and formic acid (4) led to the desired p53-MDM2 antagonist (5) (for the detailed description of synthetic procedures and analytical data see Supporting Information). The resulting racemic mixture was subjected to preparative chiral separation yielding the two enantiomers, (R)-5a and (S)-5b (see the section 1.5 of Supporting Information, Fig. S1 and Table S1 for the details on the separation of enantiomers). The two latter compounds were hydrolyzed into the corresponding acids (R)-6a and (S)-6b (Fig. 1) .
The compounds 5 and 6 bind to MDM2
Three complementary assays based on independent physicochemical principles, fluorescence polarization (FP), 1 H-15 N HSQC NMR, and microscale thermophoresis (MST) were used to test the in vitro activity of the compounds. The FP assay was performed to compare the MDM2-p53 inhibitory activity of new batches of the compounds with the data reported in our previous study [22] . The assay was performed for the enantiomers R of the compounds (5) and (6), as these enantiomers presented higher activity in our previous study [22] . Both compounds presented K i values much lower than 1 lM, which corresponds well with the values reported previously (see Tables 1 and S2). 1 H-15 N HSQC NMR titration was used to verify the results of the FP assay. This method is based on monitoring the chemical shift changes in protein amide backbone resonances upon protein interaction with a small molecule [23] [24] [25] . The binding to MDM2 protein was confirmed for all the final compounds, i.e., (R)-5a, (S)-5b, (R)-6a and (S)-6b. The pattern of chemical shift changes observed for the compound (R)-6a was similar to the pattern reported in our previous work and also correlates well with the FP data [22] . Tight binding, characterized by the slow chemical exchange and observed as doubling of NMR signals [26] was noted for the compounds (R)-5a, (R)-6a, and (S)-6b (Figs 2, S2 and S3). Such a behavior is characteristic for the compounds with dissociation constants K D values below 1 lM. NMR results showed that acids (R)-6a and (S)-6b were more potent compared to their esters (R)-5a and (S)-5b (Table 1) . This was most evident for the compounds (S)-5b/6b, for which only acid (S)-6b, but not the ester (S)-5b, was able to evoke peaks doubling (Fig. S4) [27, 28] . The calculated K D for (S)-5b was 10.7 AE 6.5 lM (Fig. S4) . The comparison of enantiomers shows that from the pair of the ester compounds (R/S)-5a/b the R enantiomer is far more potent than the S enantiomer. In the case of acids (R/S)-6a/b, both enantiomers exhibit similar potency in the tested system. The given K i values are retrieved from our previous work [22] .
Finally, a third assay, microscale thermophoresis (MST) was employed to cross-validate the binding affinity of tested compounds. The technique relies on the thermophoretic motion of the molecule in a temperature gradient induced by a high precision IR-laser beam. Changes in the molecular diffusion resulting from binding events provide information on affinity [29, 30] .
In the experimental setup, the concentration of a fluorescently labeled MDM2 was fixed at 100 nM, whereas the concentration of an unlabeled binding compound was varied. All the tested compounds showed an affinity toward MDM2 in the low lM range (Table 1 , raw data available in the Supporting Information). The K D values were 7.0 lM and 1.3 lM for the (R)-6a and (S)-6b enantiomers, respectively. Likewise, the binding of ester enantiomers, (R)-5a and (S)-5b to the fluorescently labeled MDM2 led to K D values of 3.0 lM and 7.7 lM, respectively.
The compounds 5 and 6 disrupt the MDM2-p53 complex As described above, the compounds 5 and 6 bind to MDM2 and are able to displace p53-derived peptide complexed with MDM2 protein. To verify if the compounds are also able to dissociate the p53-MDM2 complex, the compounds were tested by the Antagonist Induced Dissociation Assay (AIDA-NMR) [31] .
The method is based on the NMR spectroscopy of the complex formed by the human p53 (residues 1-321) and human MDM2 (residues 1-125), and its subsequent dissociation upon the titration with the inhibitor. Usually the methodology is performed using indole residues of Trp23, Trp53, and Trp91. Therefore, we decided to perform a proton AIDA-NMR experiments for all the compounds with FP Ki values below 1 lM, and defined as 'tight binders' by the NMR spectroscopy, i.e., the compounds (R)-5a, (R)-6a, and (S)-6b), along with a known MDM2 antagonist, nutlin-3a as an reference. On the 1D proton spectrum of the reference p53-MDM2 complex shows only two peaks, corresponding to Trp91 and Trp53 of p53 (Fig. S5) . The peak corresponding to the Trp23 is not visible, because this residue is buried inside the protein complex, as it participates in the complex formation. The residues Trp53 and Trp91 are accessible for NMR spectroscopy even when p53 is bound to MDM2 and their corresponding signals are not expected to vary between MDM2-bound and unbound p53. Upon the titration of the complex with MDM2 antagonists, the formation of the peak originating from Trp23 is observed, as exemplified for nutlin-3a (Fig. S5A ). This indicates the release of p53 from its complex with MDM2. The p53-MDM2 complex titrated with each of the tested compounds resulted in similar observations, suggesting that the compounds indeed disrupt p53-MDM2 complex in solution ( Fig. S5B-D) .
(R)-6a binds to MDM2 with a classical threefinger binding mode
To characterize the structural basis of the interactions of the evaluated compounds at the hydrophobic pocket of the p53-binding domain of MDM2, we determined the crystal structure of (R)-6a in complex with MDM2(18-125) (fragment of MDM2 comprising residues 18-125). The compound (R)-6a was chosen as the most potent one in the FP assay. The obtained crystals diffracted to 2.0 A resolution and contained one protein-inhibitor complex in the asymmetric unit, with (R)-6a well defined by its electron density ( Fig. S6 ) and with no additional inhibitor molecules found within the structure (data collection and refinement statistics shown in the Table S3 in the Supporting Information).
(R)-6a binds to MDM2 with a classical three-finger binding mode (Fig. 3A,B) , occupying all three p53-binding subpockets defined by following residues of p53: Phe19, Trp23, and Leu26 (Fig. 3C ). Concerning the similarities to the native interaction, the binding of (R)-6a into the cleft of MDM2 is primarily stabilized by hydrophobic interactions with Leu54, Leu57, Gly58, Ile61, Met62, Tyr67, Val75, Phe86, Phe91, Val93, Ile99, Tyr100, and Ile103 (residues labeled at Fig. 4A ). Another resemblance is noticed for the 6-chloroindole substituent of (R)-6a that inserts into a Trp23 subpocket and assumes an orientation almost identical to the Trp side chain of p53 in the native p53-MDM2 complex. The chlorine atom introduced in (R)-6a stabilizes the interaction at the bottom of the hydrophobic cleft. Such an arrangement of 6-chloroindole moiety repeating the p53's Trp23 indole interaction follows a canonical binding observed in many different classes of MDM2 inhibitors [32] . Further, comparable to p53 interaction, the NH group within 6-chloroindole participates in a hydrogen bond with the carbonyl oxygen of Leu54 (length of 2.6 A, Fig. 4A ).
Concerning the remaining MDM2 subpockets which are naturally occupied by p53's Phe19 and Leu26, the differences can be easily spotted as the character (alkyl/aryl) of substituents of (R)-6a differs from p53's side chains. The Phe19 subpocket accommodates the tert-butyl substituent of (R)-6a directed at Tyr67. The 3,4,5-trifluorobenzyl substituent of (R)-6a fills the Leu26 subpocket pointing toward Tyr100 and is involved in p-stacking with His-96 side chain (Fig. 4A ) [22] . Moreover, this stacking results also in the change of the overall shape of Leu26 subpocket when compared to the native interaction, as in case of (R)-6a it gets 'closed' and less exposed to the solvent.
Additionally, the inhibitor's scaffold and carboxylic group of (R)-6a further contribute to the formation of several hydrogen bonds with water molecules interacting with MDM2 (Fig. 4B) . Taken together, hydrophobic interactions, hydrogen bonds and p-stacking define the high affinity of (R)-6a to p53-binding pocket of MDM2.
The MDM2 antagonist (R)-5a activates p53 and induces the expression of p53-dependent genes
The disruption of the p53/MDM2 interaction in p53 wt cells leads to the release of transcriptionally active p53, which then regulates the expression of a panel of target genes. The protein p21 is a product of such a well-known p53-regulated gene and changes in its expression are often examined to track the activation of p53.
To test the bioactivity of the compounds, human osteosarcoma U-2 OS cells were treated with increasing concentrations of the compounds (R)-5a and (R)-6a for 24 h, followed by western blot analysis of the expression of p21 protein. As a control, two MDM2 antagonists were used: Nutlin-3 and RG7388 as one of the best-studied compounds and one of the most potent antagonists, respectively. Both compounds increased the expression of p21 and p53 in U-2 OS cells (Fig. 5A ). The compound (R)-5a induced a strong expression of both p53 and p21 protein, proving the efficient release of p53 from the negative influence of MDM2 (Fig. 5A ). This effect was observed at the concentrations of 5 and 10 lM of the compound. The carboxylic acid version of (R)-5a, compound (R)-6a, did not alter the expression of the examined proteins (Fig. 5A) .
To check the stereoselectivity of the compound 5 in living cells, both enantiomers of the compound 5, (R)-5a and (S)-5b, were tested in a western blot experiment. The analysis confirmed a strong activity of (R)-5a, while the enantiomer (S)-5b was found inactive (Fig. 5B) . This corresponded well with the FP, NMR, and MST results, where the enantiomer S was found less active than the R enantiomer (Table 1) .
While the increase of p53 protein levels in response to MDM2 antagonists is due to increased stability of the p53 protein, the increase of expression of p53 targets, p21 and MDM2, is related to transcriptional induction of CDKN1A and MDM2 genes, respectively. To verify if the increased protein levels are associated with increase abundance of corresponding transcript, a real-time PCR was performed with the detection of MDM2, CDKN1A, and TP53 transcripts. The results clearly show that the treatment of U-2 OS cells with MDM2 antagonists, RG7388 or (R)-5a, leads to a significant increase of MDM2 and CDKN1A transcripts (Fig. 5C ). This suggests that the (R)-5a compound indeed indices transcriptional activity of p53 in living cells. The statistical significance was evaluated using a t-test versus DMSO-treated control cells: *P < 0.05, **P < 0.01, ***P < 0.001.
The compound (R)-5a selectively inhibits the growth of p53 wt cells
To evaluate the selectivity of (R)-5a toward p53 wt cells, a cell viability MTT assay was performed on two p53 wt cell lines, U-2 OS and SJSA-1, and one p53 del cell line, namely SAOS-2. Both p53 wt cells were more susceptible to (R)-5a than SAOS-2 cells with the resulting IC 50 values of 3.3 lM and 2.7 lM for U-2 OS and SJSA-1 cells, respectively, and 13.6 lM for SAOS-2 cells (Fig. 5D) .
The anticancer activity of MDM2 antagonists results mainly from the induction of cell cycle arrest [33] . To analyze the induction of cell cycle arrest by (R)-5a, flow cytometry analysis was performed. A positive control compound RG7388 decreased the percentage of S-phase cells from 55% to 0.5% in U-2 OS cells at the concentration of 5 lM (Fig. 5D) . Similarly, (R)-5a induced cell cycle arrest as demonstrated by the decrease of the percentage of S-phase cells from 55% to 16% and 1.4% at the concentrations of 5 and 10 lM, respectively (Fig. 5D ). Even stronger cell cycle arrest was observed for SJSA-1 cells that are known to be extremely sensitive to MDM2 antagonists, but no effect was noted for p53 del SAOS-2 cells supporting the activity and selectivity of the compound (Fig. S7) .
The compound (R)-5a induces apoptosis in p53 wt
SJSA-1 cells
The activation of p53 with the use of MDM2 antagonists leads not only to the growth inhibition of p53 wt cells but also to the induction of apoptosis, although this effect is restricted to a subgroup of p53 wt cells [33] [34] [35] [36] . To verify the proapoptotic properties of the MDM2 antagonist (R)-5a a caspase 3/7 activity assay was performed with the use of U-2 OS and SJSA-1 osteosarcoma cells. The cells were treated with staurosporine (positive control), RG7388 (potent MDM2 antagonist), (R)-5a (active MDM2 antagonist), or (R)-6a (inactive, de-esterified version of the (R)-5a compound). Staurosporine induced apoptosis in both cell lines. The active (R)-5a compound showed the activity similar to RG7388-it induced apoptosis only in SJSA-1 cells, and not in U-2 OS cells. Although both cell lines possess wild-type p53 protein, SJSA-1 is known to be highly susceptible to apoptosis induced by MDM2 antagonists [33] . Altogether, the results suggest that the compound (R)-5a presents the bioactivity characteristic for other, well-known MDM2 antagonists.
Discussion
In previous studies, we have reported new scaffolds for the design and optimization of MDM2 antagonists, synthesized in one-step multicomponent reactions. We have also performed an exhaustive scanning of fluorine substitutions at the phenyl group of the indole-based compound and provided the proof of the optimized properties of some of the resulting fluoro-substituted compounds. Here, we investigated in detail the strongest MDM2 binder from the previous series. By using three different biophysical techniques, we have observed strong MDM2 binding of all four final compounds. In accordance with the binding studies, the (R)-5a enantiomer showed concentration-dependent upregulation of p21 and growth inhibition in different p53 wild-type cell lines. Moreover, the compound showed induction of cell cycle arrest in different wildtype p53 cell lines in low lM concentrations, comparable to the clinical compound RG7388. In contrast, the less-binding (S)-5a enantiomer was not bioactive in vitro. Similarly, the nonesterified compound (R)-6a had no activity in cells, suggesting that the esterification is necessary for obtaining the biological activity. This may be due to increased cell permeability or compound stability.
Currently, several second-and third-generation MDM2 antagonists are available, with some prominent examples that have entered clinical trials and are evaluated for the treatment of cancer patients [5] . The compound (R)-5a, presented in this manuscript shows a decent and promising in vitro activity, including reactivation of p53 in p53 wt cancer cells. However, the structure of the compound would require further development before entering in vivo examination, as its activity is revealed at relatively high concentrations (above 1 lM). The crystal structure of (R)-6a, the deesterified counterpart of the (R)-5a compound, bound to MDM2 protein may help in planning further structure optimization steps. Our recent work suggests that further extending of the compound residue substituents leads to the forced opening of a fourth binding pocket, which, along with the classical Phe19, Trp23, and Leu26 binding pockets, may facilitate the interaction and potentiate the MDM2-antagonizing properties of the compound [13] . For sure the great advantage of the MDM2 antagonist (R)-5a described in this manuscript lies in its synthesis process, which leads to the generation of a complex chemical entity in a one-step, four-component Ugi reaction. The structure of the compound (R)-5a will be further developed in the future to provide better potency and drug-like properties.
Materials and methods

Protein expression and purification
Fragments of human MDM2 (residues: 1-118 in pET46; 18-125 -in pET20) were expressed in the Escherichia coli BL21-CodonPlus (DE3) RIL strain. Cells were cultured in a total volume of 5 l of LB or minimal medium at 37°C and induced with 1 mM IPTG at OD 600 nm of 0.8. Protein was expressed for 5 h at 37°C. Cells were collected by centrifugation (20 min, 5000•g), resuspended in 120 mL PBS with protease inhibitor cocktail and lysed by sonication. Inclusion bodies that were collected by centrifugation (30 min, 18 000•g), washed twice with 120 mL PBS containing 0.05% Triton-X100 and once with 120 mL PBS and centrifuged (15 min, 15 000•g) after each wash. Purified inclusion bodies were solubilized in 20 mL of 6 M guanidine hydrochloride in 100 mM Tris/HCl, pH 8.0, containing 1 mM EDTA and 10 mM b-mercaptoethanol. The protein was dialyzed against 1 L of 4 M guanidine hydrochloride, pH 3.5 supplemented with 10 mM b-mercaptoethanol. Following, the protein was refolded by dropwise addition into 1 L of 10 mM Tris/HCl, pH 7.0, containing 1 mM EDTA and 10 mM b-mercaptoethanol and slow mixing overnight at 4°C. Ammonium sulfate was added to the final concentration of 1.5 M, mixed for 2 h and centrifuged for 40 min at 10 000•g. The refolded protein was recovered on Butyl Sepharose 4 Fast Flow previously equilibrated with refolding buffer containing 1.5 M (NH 4 ) 2 SO 4 . The column was washed and the protein was eluted using 100 mM Tris/HCl, pH 7.2, containing 5 mM b-mercaptoethanol. Fractions containing the protein were pooled and purified by gel filtration on S75 16/600 column in 5 mM Tris/HCl pH 8.0 containing 50 mM NaCl and 5 mM b-mercaptoethanol (crystallization buffer) or in 50 mM phosphate buffer pH 7.4 containing 150 mM NaCl and 5 mM DTT (FP/NMR buffer).
MDM2-p53 complex expression and purification for the AIDA-NMR
Human MDM2-p53 complex (residues: 1-125 of Mdm2 with poly-histidine tag; 1-321 of p53 in pETDuet-1) were expressed in the Escherichia coli BL21-CodonPlus (DE3) RIL strain. Cells were cultured in a total volume of 4 L of LB and induced with 0.5 mM IPTG at OD 600 nm of 0.7. Protein was expressed for 16 h at 20°C. Cells were collected by centrifugation (20 min, 5000 g), resuspended in 140 mL of 50 mM monosodium phosphate buffer pH 8.0, containing 300 mM sodium chloride and 10 mM imidazole and lysed by sonication. Soluble protein complexes were recovered on Ni-NTA resign previously equilibrated with resuspension buffer. The column was washed with 50 mM monosodium phosphate, pH 8.0, containing 300 mM sodium chloride and 20 mM imidazole and the protein was eluted using 50 mM monosodium phosphate, pH 8.0, including 300 mM sodium chloride and 250 mM imidazole. Fractions containing the complex were pooled and purified by gel filtration on S200 16/60 column in PBS.
Fluorescence polarization assay
Fluorescence Polarization (FP) assay was used to monitor interactions between MDM2 and its antagonists. For each assay, fresh protein stocks of MDM2 (1-118) were thawed and the protein concentrations were determined using the Bradford method. Assay buffer contained 50 mM NaCl, 10 mM Tris pH 8.0, 1 mM EDTA, and 5 % DMSO. All the experiments were prepared in duplicates.
The binding affinity of the mutant p53 peptide (P2 peptide, sequence: LTFEHYWAQLTS, labeled with carboxyfluorescein) toward MDM2 was first determined. For this purpose, 10 nM of the fluorescent P2 peptide was contacted with serial dilutions of tested protein (range from 750 to 0.012 nM) in a final volume of 100 lL and fluorescence polarization was determined. K D was determined by fitting the curve described by below equation to experimental data:
where FP is the determined value of fluorescence polarization, FP min -fluorescence polarization for ligand only, FP max -fluorescence polarization at protein concentration saturating the ligand, and c-protein concentration. Competition binding assay was performed using 10 nM fluorescent P2 peptide and optimal protein concentration for the measurement calculated based on determined K D according to Huang et al. (f 0 = 0.8) [37] . Tested compounds were dissolved in DMSO at 50 lM. Serial dilutions (50 lM to 0.05 lM) were prepared in DMSO. Nutlin-3a was used as positive controls for MDM2. Fluorescence polarization was determined using Tecan InfinitePro F200 plate reader with the 485 nm excitation and 535 nm emission filters. The fluorescence intensities, parallel and perpendicular to the plane of excitation, were determined in Corning black 96-well NBS assay plates at room temperature. Fluorescence polarization values were expressed in millipolarization units (mP). Inhibition curves were fitted to obtain K i values.
NMR experiments
Uniform
15
N isotope labeling was achieved by the expression of Mdm2 (residues 1-118) protein in the M9 minimal media containing 15 NH 4 Cl as the sole nitrogen source. The final step of purification of Mdm2 for NMR consisted of gel filtration into the NMR buffer (50 mM phosphate buffer pH 7.4 containing 150 mM NaCl, 5 mM DTT). 10% (v/v) of D 2 O was added to the samples to provide lock signal. Water suppression was carried out using the WATER-GATE sequence [38] . All the spectra were recorded at 300K using a Bruker Avance 600 MHz spectrometer with Cryo Platform. 
Microscale thermophoresis
Twenty micromolar of the purified human MDM2 protein (residues 1-118) was fluorescently labeled following NanoTemper's Protein Labeling Kit RED-NHS protocol for N-hydroxysuccinimide (NHS) (L001-NanoTemper Technologies, Munich, Germany), coupling NT647 dye to lysine residues. The labeled protein was pretested in standard treated, hydrophilic, hydrophobic, and premiumcoated MST capillaries (NanoTemper Technology) for protein adsorption to the capillary wall; this was evaluated by capillary scans performed by Monolith NT.115 prior to MST experiments.
For MST experiments, the concentration of the labeled MDM2 was kept constant at 100 nM while the unlabeled binding compounds were titrated in 1 : 1 ratio within 16 twofold serial dilutions. The compounds stocks were prepared in DMSO (100 mM) and diluted into the assay MST optimized buffer (50 mM Tris/HCl buffer, pH 7.6 containing 150 mM NaCl, 10 mM MgCl 2 , and 0.05% to reach the final concentration of the assay. Four compounds were tested for binding affinity toward MDM2: 5a,b, and 6a,b. Each compound was titrated against a specific amount of MDM2 starting from the highest concentration of 1.25 mM for (R)-6a, (S)-6b, and (R)-5a compounds containing 5% DMSO, except (S)-5a with 0.032 mM as starting highest concentration and 1.5% final DMSO concentration. For the subsequent measurements, serial dilutions were prepared, mixed with MDM2 solution of 200 nM in a final volume of 20 lL and incubated for 4 min. Followed by loading of each reaction mixture into a capillary, placed on the sample tray and then finally transferred to the instrument. MST measurements were taken in Premium-coated capillaries (MO-K025, NanoTemper Technologies) on a Monolith NT.115 instrument using 40% MST power, an LED excitation source with k = 625n at 22°C with laser off/on times of 5 s. NanoTemper MO. AFFINITY ANALYSIS v2.2.4 software (NanoTemper Technologies) was used to fit the data and determine the K D values.
Protein crystallization
Human MDM2 was prepared in 5 mM Tris pH 8.0, 50 mM NaCl, and 5 mM b-mercaptoethanol. Molar excess (3x) of the inhibitor (50 mM stock in DMSO) was added and the MDM2-inhibitor complex was concentrated to 20 mgÁmL À1 .
Screening for crystallization conditions was performed using a sitting drop vapor diffusion method. Crystals of the MDM2-inhibitor complexes appeared after a few days at 4°C in 0.1 M Bis-Tris pH 6.5 containing 20% (w/v) PEG 5000 MME. MDM2 crystals were flash-cooled in liquid nitrogen without further cryoprotection.
Data collection and crystal structure determination
The diffraction data were collected at 14.1 beamline at the BESSY II, Berlin, Germany. The data were indexed and integrated using XDS [41] . The further computational steps were performed with programs contained in the CCP4 package [42] or PHENIX [43] . The data were scaled and merged using SCALA [44] . Initial phases for MDM2 structures were obtained by molecular replacement using PHASER [45] and MDM2 structure derived from PDB ID 3TJ2 (MDM2 18-125) as a search model. The models were manually built in the resulting electron density maps using COOT [46] . Restrained refinement was performed using PHENIX [43] . After several cycles of model building and refinement, the electron densities defining the ligands in MDM2 structures became clearly visible and the ligand molecule was introduced into the model. The restrains defining the ligand molecule were prepared using JLIGAND [47] . Water molecules were added using Coot and subsequently manually inspected. The data collection and refinement statistics for all complexes are summarized in Table S2 . The structure factors and final models were deposited into PDB with the following accession number: 5OAI.
Cell lines-culture and treatment
Human osteosarcoma cell lines U-2 OS (p53 wt ) and SAOS-2 (p53 del ) were purchased from ECACC (Sigma Aldrich, Saint Louis, MO, USA) and cultured in McCoy's 5A
Medium containing L-glutamine (Lonza) and supplemented with 10% fetal bovine serum (FBS, Biowest). Human osteosarcoma SJSA-1 (p53 wt ) cell line was purchased from ATCC (LGC Standards) and cultured in RPMI-1640 medium containing L-glutamine and supplemented with 10% FBS. The cells were cultured at 37°C and 5% CO 2 in a humidified atmosphere and tested for Mycoplasma contamination using the PCR-based method [48] . All compounds were prepared as 50 mM stock solutions in DMSO. The compounds were further diluted in DMSO (working solutions, 0.2-20 mM) and added to the culture medium for the cell treatment. The final concentration of DMSO was kept constant and its final concentration was below or equal 0.5%.
Western blot analysis
U-2 OS cells (120 000 cells per well) were seeded on 12-well transparent plates (Falcon). On the next day, the compounds were added and the cells were cultured for an additional 24 h. Cells were lysed with RIPA buffer (Sigma Aldrich) supplemented with protease inhibitor cocktail (Sigma Aldrich). The protein lysates were clarified by centrifugation and analyzed on 12% SDS polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA). The proteins were transferred to PVDF membrane (Merck Millipore, Burlington, MA, USA). The membranes were blocked for 1 h in 4% bovine serum albumin (BSA, Bioshop, Burlington, ON, Canada) in TBS-N buffer (150 mM NaCl, 20 mM Tris/HCl pH 7.6, containing 0.1% Nonidet). Membranes were probed with rabbit monoclonal anti-p21 antibody (1 : 2000, Cell Signaling, cat. no. 2947) and rabbit monoclonal anti-GAPDH antibody (1 : 4000, Cell Signaling, Danvers, MA, USA, cat. no. 2118). Anti-rabbit antibody conjugated with horseradish peroxidase (1 : 2000, Cell Signaling, cat. no. 7074) was used to detect the primary antibodies. The blots were developed with Clarity Western ECL Substrate (Bio-Rad) and visualized using ChemiDoc MP System (Bio-Rad). Densitometry analysis was performed using IMGELAB software (Bio-Rad).
RNA isolation and real-time PCR
For the isolation of RNA, 120 000 U-2 OS cells were seeded on 12-well plates (Falcon, Corning, NY, USA). The next day, the cells were treated for 6 h with 5 lM RG7388, 10 lM (R)-5a or DMSO as a control. The total RNA was isolated and purified using PureLink RNA MiniKit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with PureLink DNase (Invitrogen, Thermo Fisher Scientific), according to the manufacturer's protocol. Subsequently, 1 lg of total RNA was used for reverse transcription, performed with the use of M-MLV Reverse Transcriptase (Promega, Fitchburg, WI, USA) and oligo-dT primer. After the synthesis, cDNA was amplified in real-time PCR, as described in the manufacturer's protocol, using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) with TaqMan Gene Expression Assays for the genes MDM2 (assay ID: Hs01066930_m1), TP53 (assay ID: Hs01034249_m1), CDKN1A (assay ID: Hs00355782_m1), and GAPDH (assay ID: Hs02758991_g1), which was used as a reference gene. The reaction was run on the Eppendorf Realplex 2 System. All samples were run in duplicates. The results were analyzed using the 'DDCt' relative quantitation method. Cell cycle analysis U-2 OS cells were seeded at 300 000 per 60•15 mm cell culture dish (Eppendorf), treated with tested inhibitors for 24 h, trypsinized and fixed with 70% ethanol. The cell concentration was adjusted to 1 9 106 cells/sample and DNA was labeled with PI-RNase solution (PBS, 5 lg mL-1 propidium iodide, 0.01 mg mL-1 RNase A) for 30 min at 25°C. The cells analyzed for cell cycle DNA content using LSRFortessa cell analyzer (BD Biosciences, San Jose, CA, USA). The cells were seeded on cell culture dishes (Eppendorf) and treated next day with DMSO (control), RG7388, or the compounds for additional 24 h. During the last hour of the treatment, the cells were pulse-labeled with 10 mM bromodeoxyuridine (BrdU, Sigma Aldrich). After that, the cells were harvested by trypsinization and fixed with 96% ethanol in À20°C for at least 24 h. Following the fixation, 10 6 cells were centrifuged and the supernatant was removed. Drop by drop, 1 mL of 2N HCl with Triton X-100 (0.5% v/v) was added while vortexing and the cells were incubated at room temperature for 30 min. The cells were centrifuged, supernatant aspirated, and the pellet resuspended in 1 mL of 0.1 M Na 2 B 4 O 7 , pH 8.5. Following the centrifugation, the supernatant was removed and the
Cell viability MTT assay
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